Rhizen Pharmaceuticals

Rhizen is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule drugs that target signal transduction networks and ion channels for the treatment of cancer, inflammation, autoimmune diseases, and metabolic disorders. Rhizen's proprietary IP in these areas aims to generate the earliest compounds in their class, which are expected to provide novel therapeutic options for these significant unmet medical needs. Rhizen is a virtual company that maximizes its impact by outsourcing for optimal efficiency to globally renowned laboratories throughout the process from preclinical to clinical development.Rhizen's business strategy includes partnering with/licensing to large pharmaceutical companies for late-stage clinical development and global marketing, while focusing on advancing the research pipeline through preclinical and early human clinical development.